Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

Journal of Neuro-Oncology

Volumn 36, Issue 1, 1998, Pages 65-70

  Buckner, Jan C ^a   Burch, Patrick A ^a   Cascino, Terrence L ^a   O'Fallon, Judith R ^a   Scheithauer, Bernd W ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain neoplasm; Eflornithine; Glioma; Interferon; Phase II

Indexed keywords

ANTINEOPLASTIC AGENT; EFLORNITHINE; POLYAMINE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ANOREXIA; ARTICLE; BRAIN HERNIA; CANCER RECURRENCE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DIARRHEA; FATIGUE; FEMALE; FEVER; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; LETHARGY; LEUKOPENIA; MALE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; SOMNOLENCE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR REGRESSION; VOMITING;

ADULT; AGED; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EFLORNITHINE; FEMALE; GLIOMA; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031776472     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005870329601     Document Type: Article

References (11)

1. Duffy DE, Santner TJ: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43: 81-93, 1987
2. Ganju V, Edmonson JH, Buckner JC: Phase I study of combined alpha interferon, alpha difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12: 25-27, 1994
3. 11C-2DG) (abstract). Proc Am Assoc Cancer Res 27: 155, 1986
4. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assn 53: 457-481, 1958
5. Kovach JS, Svingen PA: Enhancement of the antiproliferative activity of human interferon by polyamine depletion. Cancer Treat Rep 69: 97-103, 1985
6. Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M: Treatment of recurrent gliomas wit eflornithine. JNCI 84: 1432-1437, 1992
7. Mahaley MS Jr, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG: Immunobiology of primary intracranial tumors. Part 10: therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63: 719-725, 1985
8. Marton LJ, Pegg AE: Polyamines as targets for theurapeutic intervention. Ann Rev Pharmacol Toxicol 35: 55-91, 1995
9. McCann PP, Pegg AE: Ornithine decarboxylase as an enzyme target for therapy. Pharmacol Therap 54: 195-215, 1992
10. Seidenfeld J, Gray JW, Marton LF: Depletion of 9L rat brain tumor cell polyamine content by treatment with D, L-alpha-difluoromethylornithine inhibits proliferation and the G to S transition. Exp Cell Res 131: 209-216, 1981
11. Yung WK, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, Salcman M, Etcubanas E: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 9: 1945-1949, 1991